Evaluate LAE102 in Healthy Subjects and Subjects With Overweight Obesity
- Conditions
- Obesity
- Interventions
- Drug: LAE102 injectionOther: Saline
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 72
- Registration Number
- NCT06493084
- Locations
- 🇨🇳
Fudan Zhongshan Hospital, Shanghai, Shanghai, China
Human Mass Balance and Biotransformation Study of [14C]Afuresertib
- Conditions
- Healthy Volunteer
- Interventions
- Drug: [14C]Afuresertib
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05489744
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
- Conditions
- Solid TumorTNBC - Triple-Negative Breast Cancer
- Interventions
- Combination Product: LAE005 + Afuresertib + Nab-Paclitaxel
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 21
- Registration Number
- NCT05390710
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Sun Yat-sen Memorial Hospital, Guangzhou, China
🇨🇳Sir RunRun Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
- Conditions
- Esophageal CancerGastric and Gastroesophageal Junction AdenocarcinomaSolid TumorNSCLCCervical CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 167
- Registration Number
- NCT05383482
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chengdu, China
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- First Posted Date
- 2021-04-20
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 256
- Registration Number
- NCT04851613
- Locations
- 🇺🇸
Providence St. Johns Health Center, Santa Monica, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Piedmont Cancer Institute, Atlanta, Georgia, United States
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 150
- Registration Number
- NCT04374630
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸US Texas Oncology, San Antonio, Texas, United States
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 49
- Registration Number
- NCT04060394
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggido, Korea, Republic of
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Associated Medical Professionals of NY, Syracuse, New York, United States
A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Drug: LAE001
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 33
- Registration Number
- NCT03843918
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
🇨🇳ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China